{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-26-000066","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-09-10T20:05:37+00:00","discovered_at":"2026-09-10T20:08:00.361832+00:00","generated_at":"2026-09-10T20:08:19.120574+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus closes $270M cash + stock buy of Alkeus; adds Stargardt drug ALK-001","bullets":["Up-front consideration: $270M cash plus 2,908,692 Tarsus shares to Alkeus equityholders.","Milestones up to $350M: $250M on US regulatory approval, $100M on first US sale; plus low-to-mid single-digit revenue share.","Adds ALK-001, Phase 3 oral for Stargardt disease, with FDA Breakthrough, Orphan, Fast Track, Rare Pediatric designations.","NORTHSTAR Phase 3 trial ongoing; topline data expected 2029.","Acquisition closed Sept 4, 2026; Alkeus becomes wholly-owned subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-26-000066","json":"https://secwatch.observer/filing/0001819790-26-000066.json","markdown":"https://secwatch.observer/filing/0001819790-26-000066.md","text":"https://secwatch.observer/filing/0001819790-26-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000066/0001819790-26-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000066/tars-20260904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T20:08:19.120574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}